New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 20mg - tablet - 20 mg - active: aripiprazole 20mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 5mg - tablet - 5 mg - active: aripiprazole 5mg excipient: hyprolose indigo carmine aluminium lake lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin;  ;  ; tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - powder for injection - 4 g/0.5 g - active: piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin     tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piptaz sandoz plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piptaz sandoz is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 169.8 mg (equivalent: venlafaxine, qty 150 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; sunset yellow fcf; povidone; magnesium stearate; microcrystalline cellulose; brilliant blue fcf; copovidone; allura red ac; purified talc; colloidal anhydrous silica; titanium dioxide; propylene glycol; ethanol; isopropyl alcohol; shellac; tert-butyl alcohol; sodium hydroxide - sandoz venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 84.9 mg (equivalent: venlafaxine, qty 75 mg) - capsule, modified release - excipient ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - sandoz venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - tacrolimus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - tacrolimus -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - tacrolimus -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - capsules - see ingredients - each capsule contains omeprazole 20,0 mg